Cargando…

Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial

INTRODUCTION: Schizophrenia is a chronic and severe mental disorder. While research focus remains mainly on negative outcomes, it is questionable whether we are placing enough emphasis on improving their sense of well-being and functioning. This could be accessed through the study of the quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaudoin, M., Potvin, S., Hudon, A., Giguère, C.-E., Dumais, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471565/
http://dx.doi.org/10.1192/j.eurpsy.2021.423
_version_ 1784789106870452224
author Beaudoin, M.
Potvin, S.
Hudon, A.
Giguère, C.-E.
Dumais, A.
author_facet Beaudoin, M.
Potvin, S.
Hudon, A.
Giguère, C.-E.
Dumais, A.
author_sort Beaudoin, M.
collection PubMed
description INTRODUCTION: Schizophrenia is a chronic and severe mental disorder. While research focus remains mainly on negative outcomes, it is questionable whether we are placing enough emphasis on improving their sense of well-being and functioning. This could be accessed through the study of the quality of life (QoL). To date, QoL prediction models mainly focused on neurocognition and psychotic symptoms, but their predictive power remained limited. OBJECTIVES: The aim is to accurately predict the QoL within schizophrenia using unsupervised learning methods. METHODS: We computed variables from 952 patients from the CATIE study, a randomized, double-blind clinical trial for schizophrenia treatment. QoL was measured using the Heinrichs-Carpenter Quality of Life Scale and potential predictors included almost all available variables: symptoms, neurocognition, medication adherence, insight, adverse effects, etc. By optimizing parameters to reach optimal models, three linear regressions were calculated: (1) baseline predictors of 12-month QoL, (2) 6-month predictors of 12-month QoL, and (3) baseline predictors of 6-month QoL. Adjustments were made to ensure that included variables were not collinear nor redundant with QoL. RESULTS: Calculated models had adjusted R-squared of 0.918, 0.922 and 0.913, respectively. Best predictors were medication side effects, sociodemographic and neurocognitive variables. Low psychotic and depressive symptoms were also included, as well as lab values suggesting the absence of problems with chloremia and calcemia. CONCLUSIONS: Calculated predictive models explain almost all subsequent QoL. It appears that physical health variables, generally omitted from mental health-related studies, have an important impact on patients’ QoL. Therefore, interventions should also consider these aspects. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9471565
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94715652022-09-29 Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial Beaudoin, M. Potvin, S. Hudon, A. Giguère, C.-E. Dumais, A. Eur Psychiatry Abstract INTRODUCTION: Schizophrenia is a chronic and severe mental disorder. While research focus remains mainly on negative outcomes, it is questionable whether we are placing enough emphasis on improving their sense of well-being and functioning. This could be accessed through the study of the quality of life (QoL). To date, QoL prediction models mainly focused on neurocognition and psychotic symptoms, but their predictive power remained limited. OBJECTIVES: The aim is to accurately predict the QoL within schizophrenia using unsupervised learning methods. METHODS: We computed variables from 952 patients from the CATIE study, a randomized, double-blind clinical trial for schizophrenia treatment. QoL was measured using the Heinrichs-Carpenter Quality of Life Scale and potential predictors included almost all available variables: symptoms, neurocognition, medication adherence, insight, adverse effects, etc. By optimizing parameters to reach optimal models, three linear regressions were calculated: (1) baseline predictors of 12-month QoL, (2) 6-month predictors of 12-month QoL, and (3) baseline predictors of 6-month QoL. Adjustments were made to ensure that included variables were not collinear nor redundant with QoL. RESULTS: Calculated models had adjusted R-squared of 0.918, 0.922 and 0.913, respectively. Best predictors were medication side effects, sociodemographic and neurocognitive variables. Low psychotic and depressive symptoms were also included, as well as lab values suggesting the absence of problems with chloremia and calcemia. CONCLUSIONS: Calculated predictive models explain almost all subsequent QoL. It appears that physical health variables, generally omitted from mental health-related studies, have an important impact on patients’ QoL. Therefore, interventions should also consider these aspects. DISCLOSURE: No significant relationships. Cambridge University Press 2021-08-13 /pmc/articles/PMC9471565/ http://dx.doi.org/10.1192/j.eurpsy.2021.423 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Beaudoin, M.
Potvin, S.
Hudon, A.
Giguère, C.-E.
Dumais, A.
Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
title Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
title_full Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
title_fullStr Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
title_full_unstemmed Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
title_short Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
title_sort prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (catie) schizophrenia trial
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471565/
http://dx.doi.org/10.1192/j.eurpsy.2021.423
work_keys_str_mv AT beaudoinm predictionofqualityoflifeinschizophreniausingmachinelearningmodelsondatafromclinicalantipsychotictrialsofinterventioneffectivenesscatieschizophreniatrial
AT potvins predictionofqualityoflifeinschizophreniausingmachinelearningmodelsondatafromclinicalantipsychotictrialsofinterventioneffectivenesscatieschizophreniatrial
AT hudona predictionofqualityoflifeinschizophreniausingmachinelearningmodelsondatafromclinicalantipsychotictrialsofinterventioneffectivenesscatieschizophreniatrial
AT giguerece predictionofqualityoflifeinschizophreniausingmachinelearningmodelsondatafromclinicalantipsychotictrialsofinterventioneffectivenesscatieschizophreniatrial
AT dumaisa predictionofqualityoflifeinschizophreniausingmachinelearningmodelsondatafromclinicalantipsychotictrialsofinterventioneffectivenesscatieschizophreniatrial